Impact of hormone replacement therapy on endogenous estradiol metabolism in postmenopausal women

被引:22
作者
Mueck, AO [1 ]
Seeger, H [1 ]
Wallwiener, D [1 ]
机构
[1] Univ Tubingen, Dept Obstet & Gynecol, Sect Endocrinol & Menopause, D-72076 Tubingen, Germany
关键词
postmenopausal women; hormone replacement therapy; estradiol metabolism;
D O I
10.1016/S0378-5122(02)00160-3
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Objectives: Changes in estradiol metabolism may play a role in the pathophysiology of different diseases, of special interest being an increase in D-ring over A-ring metabolites for the risk of breast cancer. In the present work we investigated the effect of exogenous estradiol therapy on endogenous estradiol metabolism in postmenopausal women. Methods: Three different studies were carried out in 126 women: in study A the women were treated for 4 weeks either with oral or with transdermal 17beta-estradiol, in study B for 4 weeks with oral or transdermal 17beta-estradiol sequentially combined with oral or transdermal norethisterone acetate, and in study C for 12 weeks either with oral 17beta-estradiol or with an oral continuous combination of 17beta-estradiol with the new progestin dienogest. As main representatives of the A- and D-ring metabolism, 2-hydroxyestrone (2-OHE1) and 16alpha-hydroxyestrone (16-OHE1), respectively, were measured in 8 h night urine using enzyme immunoassay technique. Results: Oral estradiol treatment resulted in a significant higher excretion of estradiol metabolites compared to transdermal treatment. Neither oral nor transdermal estradiol induced a significant change in the ratio of 16-OHE1 to 2-OHE1. The addition of oral or transdermal norethisterone acetate to estradiol did not alter on average the endogenous estradiol metabolism, although in individual patients a significant increase in 16-OHE1 metabolism was observed only with oral norethisterone. The continuous oral addition of dienogest did not lead to any significant change in estradiol metabolism. Conclusions: These results indicate that oral estradiol replacement therapy enhances the quantity of circulating estradiol metabolites. This may have a more negative impact on estrogenic target cells as compared to transdermal application. Progestin addition to estradiol replacement therapy seems to have no major impact on endogenous estradiol metabolism. Further studies, however, are necessary to evaluate the progestin effect in possible pre-disposed patients. (C) 2002 Published by Elsevier Science Ireland Ltd.
引用
收藏
页码:87 / 93
页数:7
相关论文
共 21 条
[1]  
Beral V, 1997, LANCET, V350, P1047, DOI 10.1016/S0140-6736(97)08233-0
[2]  
Bradlow HI, 1996, J ENDOCRINOL, V150, pS259
[3]   Cumulative risk of breast cancer to age 70 years according to risk factor status: Data from the Nurses' Health Study [J].
Colditz, GA ;
Rosner, B .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 2000, 152 (10) :950-964
[4]  
Kabat GC, 1997, CANCER EPIDEM BIOMAR, V6, P505
[5]   Estradiol metabolism during oral and transdermal estradiol replacement therapy in postmenopausal women [J].
Lippert, TH ;
Seeger, H ;
Mueck, AO .
HORMONE AND METABOLIC RESEARCH, 1998, 30 (09) :598-600
[6]   The impact of endogenous estradiol metabolites on carcinogenesis [J].
Lippert, TH ;
Seeger, H ;
Mueck, AO .
STEROIDS, 2000, 65 (07) :357-369
[7]  
Magnusson C, 1999, INT J CANCER, V81, P339, DOI 10.1002/(SICI)1097-0215(19990505)81:3<339::AID-IJC5>3.3.CO
[8]  
2-Y
[9]   Do urinary oestrogen metabolites predict breast cancer? Guernsey III cohort follow up [J].
Meilahn, EN ;
De Stavola, B ;
Allen, DS ;
Fentiman, I ;
Bradlow, HL ;
Sepkovic, DW ;
Kuller, LH .
BRITISH JOURNAL OF CANCER, 1998, 78 (09) :1250-1255
[10]   Changes in levels of urinary estrogen metabolites after oral indole-3-carbinol treatment in humans [J].
Michnovicz, JJ ;
Adlercreutz, H ;
Bradlow, HL .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1997, 89 (10) :718-723